The document summarizes the annual general meeting of Innovotech Inc. held on April 20, 2010 in Edmonton, Alberta. Key items included electing new directors, reviewing the company's financial results for 2009 which showed increased revenue but continued losses, and setting objectives for 2010 which focused on generating revenue from products like bioFILM PA and Agress, expanding their claims and markets, and developing new product candidates from silver periodate. The meeting also provided business updates on progress and plans for both existing and pipeline products.

1. Innovotech Inc.
Annual General Meeting
20 April 2010
Edmonton, Alberta
www.innovotech.ca © Innovotech, 2009

2. Innovotech Inc.
AGENDA
 Welcome
 Formal Administrative Business
 Adjournment of AGM
 Business Update
 Q&A
www.innovotech.ca © Innovotech, 2009

3. Innovotech Inc.
Formal Administrative Business
www.innovotech.ca © Innovotech, 2009

4. Innovotech Inc.
Election of Directors:
 Dr Lorne Babiuk
 Mr Kerry Brown
 Mr Bruce D. Hirsche Q.C.
 Dr Wolfgang H. Muhs
 Mr John Pinsent
 Dr Gerard Tertzakian
 Dr James Timourian
www.innovotech.ca © Innovotech, 2009

5. Innovotech Business Update

6. 2009 – Moving to Market
Objectives & Performance in 2009
www.innovotech.ca © Innovotech, 2009

7. 2009 Financial Results
2009 2008
Revenue $1,453,924 $1,164,035
Gross Margin $813,629 $695,409
Overhead Costs $984,178 $909,588
R&D Expenditures $809,326 $708,007
EBIT ($1,136,783) ($983,261)
Accumulated Deficit ($3,618,938) ($2,491,735)
Shares Outstanding (wa) 23,985,784 21,907,352
Cash Reserves (Dec 31) $1,375,559 $2,120,859
www.innovotech.ca © Innovotech, 2009

8. bioFILM PA - Objectives
bioFILM PA goals for 2009:
 Revenue
 Expand through commercial partner
Path:
 Canada: Maintain current plan
 USA: “Research Use Only” through Partner
 Convert to dry panel
www.innovotech.ca © Innovotech, 2009

9. bioFILM PA -Stakeholders
Alberta Health Laboratory
Payer User
IOT
Patients Doctors
Recipient Decision-maker
www.innovotech.ca © Innovotech, 2009

10. bioFILM - Market potential
Market - bioFILM PA: Canada US World
 Cystic Fibrosis $2.4M $24M $50M
 Ventilator Associated Pneumonia $35M $70M
 Other (burns, wounds) tbd
Market – bioFILM SA: Canada US World
 Catheters
 Dialysis
 Other (CF, VAP)
Total >$150M
www.innovotech.ca © Innovotech, 2009

11. bioFILM PA – 2010 Objectives
 Revenue in Canada
 Published paper
 Health economic evaluation
 Enter other markets
 US through private diagnostic laboratory
 Israel
 SA development
 Low cost and quick development
 Augments PA disease use (CF and VAP)
www.innovotech.ca © Innovotech, 2009

12. Agress – Objectives
Agress goals for 2009:
 Regulatory approval for pulses
 Commercial agreement
Path:
 Maintain current Co interest
 Potential reg filing for Fire Blight
 Develop AUS R&D
 Launch in N America for pulses post-09
www.innovotech.ca © Innovotech, 2009

13. Agress – PMRA (Canada)
Current situation: New submission:
 Innovotech denied waiver  Determine EPA stance
claims  Use Syngenta regulatory
 Asked to re-submit with team
expedited review for  Evaluate current consultants
approved components  8 crops, 25 diseases, 2 use
 Fees partially refunded patterns
 4 crops, 13 diseases, 1 use
pattern
www.innovotech.ca © Innovotech, 2009

14. Agress – Syngenta partnership
 Agress to be used as “anti-bacterial” component of many
products
 Syngenta press release on partnership
 Post-trade show orders of 1.5kg of Agress
 Syngenta (US) interest in Pithium data in corn
www.innovotech.ca © Innovotech, 2009

15. Agress – 2010 Objectives
 Expand product claims
 Crop, Disease and Use pattern
 Incorporate Syngenta trials
 Remove regulatory hurdles
 Meet with agencies
 Draw on external scientific expertise
 Maintain flexibility with other companies
www.innovotech.ca © Innovotech, 2009

16. Silver Periodate opportunity
 Unique properties
 Patentable discovery
 Interest of medical device and agriculture companies
 Assembly of internal team
www.innovotech.ca © Innovotech, 2009

17. 2010 – Objectives
Our goals for 2010:
 bioFILM PA™  Revenue
 Enter US market
 Agress  Expand claims
 Remove regulatory hurdles
 R&D  Product candidate from Silver periodate
 Develop bioFILM SA
 Photo-dynamic approval as sanitizer
 Contract Research  Revenue growth
www.innovotech.ca © Innovotech, 2009

18. Contact Information
Ken Boutilier, President
Innovotech Inc.
ken.boutilier@innovotech.ca
Ph: 780-448-0585 ext 221
Fax: 780-424-0941
www.innovotech.ca © Innovotech, 2009

19. www.innovotech.ca © Innovotech, 2009

20. 2008 Summary - Agress™
Factors:
Seed & Foliar  Treatment is based on
All crops disease pressure
World  Crop guarantees by
$20B+ Seed Treatment, sellers increases
All crops treatments
North America  A suitable antibacterial
$120M is lacking
 Formulations are as
Seed Treatment, important as “actives”
Pulse crops  Agress will be in a
North America combination with other
$3-5M agents
www.innovotech.ca © Innovotech, 2009

21. Agress – Market Potential
Markets
100% Canola
Vegetables/ Fruit Trees/
Horticulture Bushes
Treatment Intensity (%)
80% Corn
Pulses
60%
Soybeans
40%
Cereals Agress is price
20% competitive in all
markets!
0%
-$500 $500 $1,500 $2,500 $3,500 $4,500
Value/Acre ($/ac)
www.innovotech.ca © Innovotech, 2009